Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1,584,707
-
Total 13F shares
-
1,626,479
-
Share change
-
+922,437
-
Total reported value
-
$454,098
-
Price per share
-
$0.28
-
Number of holders
-
20
-
Value change
-
+$256,532
-
Number of buys
-
10
-
Number of sells
-
2
Institutional Holders of Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) as of Q1 2025
As of 31 Mar 2025,
Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) was held by
20 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,626,479 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, Shay Capital LLC, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, CITADEL ADVISORS LLC, TWO SIGMA SECURITIES, LLC, Point72 Asset Management, L.P., TWO SIGMA INVESTMENTS, LP, XTX Topco Ltd, and Tower Research Capital LLC (TRC).
This page lists
20
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.